Identification of histone deacetylase 8 as a novel therapeutic target for renal fibrosis

FASEB J. 2020 Jun;34(6):7295-7310. doi: 10.1096/fj.201903254R. Epub 2020 Apr 12.

Abstract

Histone deacetylases (HDACs) have been shown to alleviate renal fibrosis, however, the role of individual HDAC isoforms in this process is poorly understood. In this study, we examined the role of HDAC8 in the development of renal fibrosis and partial epithelial-mesenchymal transitions (EMT). In a murine model of renal fibrosis induced by unilateral ureteral obstruction (UUO), HDAC8 was primarily expressed in renal tubular epithelial cells and time-dependently upregulated. This occurred in parallel with the deacetylation of cortactin, a nonhistone substrate of HDAC8, and increased expression of three fibrotic markers: α-smooth muscle actin, collagen 1, and fibronectin. Administration of PCI34051, a highly selective inhibitor of HDAC8, restored acetylation of contactin and reduced expression of those proteins. PCI34051 treatment also reduced the number of renal tubular epithelial cells arrested at the G2/M phase of the cell cycle and suppressed phosphorylation of Smad3, STAT3, β-catenin, and expression of Snail after ureteral obstruction. In contrast, HDAC8 inhibition reversed UUO-induced downregulation of BMP7 and Klotho, two renoprotective proteins. In cultured murine proximal tubular cells, treatment with PCI34051 or specific HDAC8 siRNA was also effective in inhibiting transforming growth factor β1 (TGFβ1)-induced deacetylation of contactin, EMT, phosphorylation of Smad3, STAT3, and β-catenin, upregulation of Snail, and downregulation of BMP7 and Klotho. Collectively, these results suggest that HDAC8 activation is required for the EMT and renal fibrogenesis by activation of multiple profibrotic signaling and transcription factors, and suppression of antifibrotic proteins. Therefore, targeting HDAC8 may be novel therapeutic approach for treatment of renal fibrosis.

Keywords: epithelial-mesenchymal transition; histone deacetylase 8; renal fibrosis; transforming growth factor β1; unilateral ureteral obstruction; β-catenin.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylation / drug effects
  • Animals
  • Cell Line
  • Down-Regulation / drug effects
  • Epithelial Cells / drug effects
  • Epithelial Cells / metabolism
  • Epithelial-Mesenchymal Transition / drug effects
  • Epithelial-Mesenchymal Transition / genetics
  • Fibrosis / drug therapy
  • Fibrosis / metabolism*
  • Histone Deacetylase Inhibitors / pharmacology
  • Histone Deacetylases / metabolism*
  • Hydroxamic Acids / pharmacology
  • Indoles / pharmacology
  • Kidney / drug effects
  • Kidney / metabolism*
  • Kidney Diseases / drug therapy
  • Kidney Diseases / metabolism*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Phosphorylation / drug effects
  • Signal Transduction / drug effects
  • Transcription Factors / metabolism
  • Transforming Growth Factor beta1 / metabolism
  • Up-Regulation / drug effects
  • Ureteral Obstruction / drug therapy
  • Ureteral Obstruction / metabolism

Substances

  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Indoles
  • PCI 34051
  • Transcription Factors
  • Transforming Growth Factor beta1
  • HDAC8 protein, mouse
  • Histone Deacetylases